| zilurgisertib (INCB00928) / Incyte |
NCT05090891 / 2021-002286-17: To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva |
|
|
| Recruiting | 2 | 60 | Europe, Canada, US, RoW | INCB000928, INB000928 will be administered QD orally, placebo | Incyte Corporation, Incyte Corporation | Fibrodysplasia Ossificans Progressiva (FOP) | 04/25 | 04/28 | | |
2020-004029-21: A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders |
|
|
| Not yet recruiting | 1/2 | 100 | Europe | Ruxolitinib, INCB000928, Tablet, Jakavi | Incyte Corporation, INCYTE CORPORATION, Incyte corporation | Anaemia associated with myelofibrosis whether as a de novo disorder (PMF) or evolve secondarily from previous PV or ET (post–PV MF or post–ET MF)., Anaemia associated with myelofibrosis, Diseases [C] - Cancer [C04] | | | | |
2020-002771-35: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma |
|
|
| Not yet recruiting | 1/2 | 80 | Europe | INCB000928, INCB000928, Tablet | Incyte Corporation, INCYTE CORPORATION, Incyte Corporation | Participants who are transfusion-dependent or present with symptomatic anemia; for MDS participants who are ineligible to receive or have not responded to available therapies for anemia and for MM after failure of available standard treatments., Participants with symptomatic anemia; for MDS participants who are ineligible to receive or not responded to available therapies for anemia, and for MM after failure of standard treatments., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 1/2 | 84 | Europe, Canada, Japan, US | INCB000928, ruxolitinib | Incyte Corporation, Incyte corporation | Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis | 11/25 | 06/26 | | |
| Completed | 1/2 | 22 | Europe, US | INCB000928 | Incyte Corporation, Incyte Corporation | Myelodysplastic Syndromes, Multiple Myeloma, Anemia | 08/24 | 08/24 | | |
NCT05099445: Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis |
|
|
| Completed | 1 | 48 | US | INCB000928 | Incyte Corporation | Renal Impairment, Hemodialysis | 02/23 | 02/23 | | |
